SG11202104611YA - T cell compositions with improved phenotypic properties - Google Patents
T cell compositions with improved phenotypic propertiesInfo
- Publication number
- SG11202104611YA SG11202104611YA SG11202104611YA SG11202104611YA SG11202104611YA SG 11202104611Y A SG11202104611Y A SG 11202104611YA SG 11202104611Y A SG11202104611Y A SG 11202104611YA SG 11202104611Y A SG11202104611Y A SG 11202104611YA SG 11202104611Y A SG11202104611Y A SG 11202104611YA
- Authority
- SG
- Singapore
- Prior art keywords
- cell compositions
- phenotypic properties
- improved phenotypic
- improved
- properties
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/464449—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464489—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862757467P | 2018-11-08 | 2018-11-08 | |
US201962821031P | 2019-03-20 | 2019-03-20 | |
US201962867499P | 2019-06-27 | 2019-06-27 | |
PCT/US2019/060477 WO2020097466A1 (en) | 2018-11-08 | 2019-11-08 | T cell compositions with improved phenotypic properties |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104611YA true SG11202104611YA (en) | 2021-06-29 |
Family
ID=70612526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104611YA SG11202104611YA (en) | 2018-11-08 | 2019-11-08 | T cell compositions with improved phenotypic properties |
Country Status (12)
Country | Link |
---|---|
US (2) | US20200188435A1 (en) |
EP (1) | EP3876979A4 (en) |
JP (1) | JP2022512948A (en) |
KR (1) | KR20210095157A (en) |
CN (1) | CN113226359B (en) |
AU (1) | AU2019375997A1 (en) |
BR (1) | BR112021008963A2 (en) |
CA (1) | CA3118757A1 (en) |
IL (1) | IL282914A (en) |
MX (1) | MX2021005372A (en) |
SG (1) | SG11202104611YA (en) |
WO (1) | WO2020097466A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113880953A (en) * | 2020-07-01 | 2022-01-04 | 华夏英泰(北京)生物技术有限公司 | T cell antigen receptor, polymer compound thereof, preparation method and application thereof |
MX2023012902A (en) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame. |
EP4321613A1 (en) * | 2021-05-07 | 2024-02-14 | Yasuhito Tokumoto | Method for producing memory t cells |
CN113388612A (en) * | 2021-06-18 | 2021-09-14 | 重庆天科雅生物科技有限公司 | Primer designed for TCR with epitope point of IYVLVMLVL and application thereof |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
JP3680219B2 (en) * | 1994-06-28 | 2005-08-10 | 独立行政法人理化学研究所 | Induction culture method of cancer cytotoxic T lymphocytes |
US6140113A (en) | 1996-03-28 | 2000-10-31 | The Johns Hopkins University | Polynucleotides encoding molecular complexes which modify immune responses |
US7973137B1 (en) | 1996-03-28 | 2011-07-05 | Johns Hopkins University | Cell compositions comprising molecular complexes that modify immune responses |
CA2250166A1 (en) | 1996-03-28 | 1997-10-02 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
US20050169898A1 (en) | 1997-04-15 | 2005-08-04 | Jianlin Gong | Cell fusions and methods of making and using the same |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
EP1257632B1 (en) | 2000-02-24 | 2007-09-12 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
US20020131960A1 (en) | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
AU2003202908A1 (en) | 2002-01-03 | 2003-07-24 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
US20040115216A1 (en) | 2002-07-12 | 2004-06-17 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
US20040224402A1 (en) | 2003-05-08 | 2004-11-11 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific T cells |
PT1956080E (en) | 2005-08-08 | 2011-12-30 | San Raffaele Centro Fond | Use of il-7 and il-15 for the genetic modification of memory t lymphocytes |
US8629098B2 (en) | 2008-01-15 | 2014-01-14 | Yale University | Compositions and methods for adoptive and active immunotherapy |
EP2370819A4 (en) | 2008-12-01 | 2012-09-19 | Univ Johns Hopkins | Diagnostic and treatment methods for cancer based on immune inhibitors |
WO2010099205A1 (en) | 2009-02-24 | 2010-09-02 | The Trustees Of The University Of Pennsylvania | Methods for treating progressive multifocal leukoencephalopathy (pml) |
US8075895B2 (en) * | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
JP5948319B2 (en) | 2010-05-14 | 2016-07-06 | ザ ジェネラル ホスピタル コーポレイション | Compositions and methods for identifying tumor-specific neoantigens |
EP2404618A1 (en) | 2010-07-07 | 2012-01-11 | Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen | Immunomodulatory protein constructs with a helical polymeric backbone. |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
CA2858115A1 (en) | 2011-12-09 | 2013-06-13 | The Johns Hopkins University | Artificial antigen presenting cells having a defined and dynamic shape |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
CN109182266A (en) | 2011-12-12 | 2019-01-11 | 细胞药物有限公司 | The method of amplifier T cell |
ES2820729T3 (en) | 2013-02-15 | 2021-04-22 | Univ Johns Hopkins | Antigen-specific T-cell redirectors |
WO2014160132A1 (en) | 2013-03-14 | 2014-10-02 | The Johns Hopkins University | Nanoscale artificial antigen presenting cells |
US11807675B2 (en) | 2013-10-03 | 2023-11-07 | The University Of Maryland, Baltimore | Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells |
ES2777304T3 (en) * | 2014-02-21 | 2020-08-04 | Colmmune Inc | TSCM cells and methods of use |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
WO2015162211A1 (en) | 2014-04-24 | 2015-10-29 | Miltenyi Biotec Gmbh | Method for automated generation of genetically modified t cells |
AU2015249376C1 (en) | 2014-04-25 | 2019-10-31 | 2Seventy Bio, Inc. | Improved methods for manufacturing adoptive cell therapies |
WO2015189357A1 (en) | 2014-06-11 | 2015-12-17 | Polybiocept Ab | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
CN107002038B (en) | 2014-09-17 | 2021-10-15 | 约翰·霍普金斯大学 | Reagents and methods for identifying, enriching and/or expanding antigen-specific T cells |
MA45488A (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | CELL CULTURE PROCESSES, KITS AND APPARATUS |
CA3003334A1 (en) | 2015-10-28 | 2017-05-04 | Life Technologies As | Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio |
MA44314A (en) * | 2015-11-05 | 2018-09-12 | Juno Therapeutics Inc | CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS |
WO2017093464A1 (en) * | 2015-12-04 | 2017-06-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of amplifying a population of antigen-specific memory cd4+ t cells using artificial presenting cells expressing hla class ii molecules |
EP3445399A4 (en) * | 2016-03-16 | 2019-10-30 | NexImmune, Inc | Production of antigen-specific t-cells |
IT201700041430A1 (en) * | 2017-04-13 | 2018-10-13 | Sarong Spa | Method and apparatus for making capsules with a filter |
JP7475684B2 (en) * | 2017-09-20 | 2024-04-30 | ネクシミューン インコーポレイテッド | Cellular compositions containing antigen-specific T cells for adoptive therapy - Patents.com |
MX2020004239A (en) * | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Process for producing a t cell composition. |
-
2019
- 2019-11-08 EP EP19883163.8A patent/EP3876979A4/en active Pending
- 2019-11-08 US US16/678,366 patent/US20200188435A1/en active Pending
- 2019-11-08 JP JP2021524392A patent/JP2022512948A/en active Pending
- 2019-11-08 CN CN201980087076.3A patent/CN113226359B/en active Active
- 2019-11-08 MX MX2021005372A patent/MX2021005372A/en unknown
- 2019-11-08 CA CA3118757A patent/CA3118757A1/en active Pending
- 2019-11-08 AU AU2019375997A patent/AU2019375997A1/en active Pending
- 2019-11-08 WO PCT/US2019/060477 patent/WO2020097466A1/en unknown
- 2019-11-08 KR KR1020217017398A patent/KR20210095157A/en unknown
- 2019-11-08 SG SG11202104611YA patent/SG11202104611YA/en unknown
- 2019-11-08 BR BR112021008963-2A patent/BR112021008963A2/en not_active Application Discontinuation
- 2019-12-09 US US16/707,309 patent/US11007222B2/en active Active
-
2021
- 2021-05-04 IL IL282914A patent/IL282914A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20200215115A1 (en) | 2020-07-09 |
EP3876979A1 (en) | 2021-09-15 |
US20200188435A1 (en) | 2020-06-18 |
AU2019375997A1 (en) | 2021-06-03 |
IL282914A (en) | 2021-06-30 |
WO2020097466A1 (en) | 2020-05-14 |
BR112021008963A2 (en) | 2021-09-14 |
JP2022512948A (en) | 2022-02-07 |
CA3118757A1 (en) | 2020-05-14 |
KR20210095157A (en) | 2021-07-30 |
MX2021005372A (en) | 2021-09-14 |
CN113226359A (en) | 2021-08-06 |
CN113226359B (en) | 2024-05-24 |
US11007222B2 (en) | 2021-05-18 |
EP3876979A4 (en) | 2022-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282914A (en) | T cell compositions with improved phenotypic properties | |
GB201813178D0 (en) | Cell | |
PL3662014T3 (en) | Polymer composition with improved mechanical properties | |
GB201803079D0 (en) | Cell | |
GB201810492D0 (en) | Composition | |
GB201811100D0 (en) | Composition | |
HUE065859T2 (en) | Polymer composition | |
GB201819540D0 (en) | T cell modification | |
GB201812145D0 (en) | Composition | |
PT3899996T (en) | Electrolyte compositions | |
GB201804434D0 (en) | Composition | |
PL3601588T3 (en) | Phenotypic characterization of cells | |
IL255664A0 (en) | Hematopoietic stem cells with improved properties | |
PL3056528T3 (en) | Segmented copolymer composition with improved properties | |
GB201807693D0 (en) | Cell | |
GB202100709D0 (en) | Polymer composition | |
SG11201911924PA (en) | Polymer compositions stabilized with organopolysulfides | |
GB201816399D0 (en) | Cell | |
GB201810024D0 (en) | Composition | |
GB201809123D0 (en) | Composition | |
GB201805918D0 (en) | Cell | |
GB201721129D0 (en) | Fuel compositions | |
GB201801596D0 (en) | Composition | |
HUE062232T2 (en) | Solid electrolyte composition | |
FI20185919A (en) | Biodiesel composition |